Evidence map›Paper›PMID 41037223›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2025

Development of a

Meng-Jie Zhang, Yirong Chen, Caixia Zhang, Xiaofeng Bian, Xiangyang Zhang, Shijia Huang, Bowen Yang, Siyan Lu, Xueting Fu, Wei Zhao and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07593209 (Development and Evaluation of 68Ga-DOTA-EphA2), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07593209 recruitingnot on this mapstarted 2026, after this paper: background citation

Development and Evaluation of 68Ga-DOTA-EphA2: A Novel Imaging Agent Targeting EphA2 for Malignant Tumor

TypeobservationalSponsorFirst Hospital of China Medical UniversityRan2026 to 2027Enrolled30ConditionsMalignant TumorArms68Ga- DOTA-EphA2 PET/CT Imaging of Malignant Tumor
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meng-Jie Zhang *General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Yirong Chen *General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Caixia ZhangGeneral Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Xiaofeng BianGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Xiangyang ZhangCollege of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
Shijia HuangGeneral Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Bowen YangGeneral Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Siyan LuGeneral Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Xueting FuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China.
Wei ZhaoDepartment of Pathology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. zhaowei_njmu@163.com.
Xu-Dong KongState Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, and Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, 429 Zhangheng Road, Shanghai, 201203, China. xudong.kong@sjtu.edu.cn.
Shuli ZhaoGeneral Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, 68 Changle Road, Nanjing, Jiangsu, 210006, China. shulizhao79@njmu.edu.cn.

Funding

National Natural Science Foundation of China 82173205
6 · The paper itself

Abstract

purposeDespite advancements in

methodsCyclic peptide CEMJ4 was identified via phage selection, and further conjugated with DOTA and radiolabeled with

resultsCEMJ4 exhibited high affinity for human erythropoietin-producing hepatocellular receptor A2 (EphA2; K

conclusionThis study identifies CEMJ4 as a promising peptide ligand for tumor-targeted radionuclide delivery and emphasizes the clinical potential of radionuclide therapy combined with immunotherapy in theranostics to enhance therapeutic precision and efficacy.

Indexed as

LutetiumPeptides, CyclicProtein Kinase InhibitorsRadioisotopesReceptor, EphA2AnimalsCell Line, TumorDrug SynergismFemaleHumansMiceMice, Inbred C57BLPositron Emission Tomography Computed TomographyTissue DistributionLutetiumLutetium-177Peptides, CyclicProtein Kinase InhibitorsRadioisotopesReceptor, EphA2Cancer immunotherapyCyclic peptideEphA2PET/CT imagingPhage selectionTheranostics

Identifiers

PMID41037223
PMCPMC12698795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.